| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/13/2005 | CN1636980A 二肽腈组织蛋白酶k抑制剂 Dipeptide nitrile cathepsin inhibitors k |
| 07/13/2005 | CN1636978A Pyrrolidinyl metalloprotease inhibitor and its application |
| 07/13/2005 | CN1636598A Methods to potentiate intravenous estramustine phosphate |
| 07/13/2005 | CN1636594A Angiostatin and use of the same for inhibition of angiogenesis |
| 07/13/2005 | CN1636592A Stabilized liquid polypeptide-containing pharmaceutical composition |
| 07/13/2005 | CN1636590A Pharmaceutical preparation containing cyclopeptide and chemotherapeutic agent or angiogenesis inhibitor |
| 07/13/2005 | CN1636589A Non-aqueous polar aprotic peptide formulations |
| 07/13/2005 | CN1636573A Vitamin-medicine composition and its use |
| 07/13/2005 | CN1636566A Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| 07/13/2005 | CN1636561A Use of at-1 receptor antagonist for treating diseases associated with an increase of at-1 receptors |
| 07/13/2005 | CN1636560A Injectable taxane derivative based compositions |
| 07/13/2005 | CN1210309C Anti-idiotype monoclonal antibodies, their use in active immunotherapy of malignant tumors and compositions containing them |
| 07/13/2005 | CN1210308C Humanized anti-HER2 monoclonal antibody, its preparation method and pharmaceutical composition thereof |
| 07/13/2005 | CN1210307C Humanized anti-CD 20 monoclonal antibody |
| 07/13/2005 | CN1210303C Human apolipoprotein polypeptide and its use in resisting vascular proliferation diseases |
| 07/13/2005 | CN1210302C Minor peptide of growth factor receptor KDR of specific combined blood vessel endothelium |
| 07/13/2005 | CN1210289C Radde anemone rhizome extract and its prepn process and use |
| 07/13/2005 | CN1210285C Remedies |
| 07/13/2005 | CN1210273C Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/13/2005 | CN1210270C Novel use of phenylheteroalkylamine derivatives |
| 07/13/2005 | CN1210263C N-hydroxy-2-(alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
| 07/13/2005 | CN1210256C Diacylhydrazine derivs |
| 07/13/2005 | CN1210250C Benzene derivatives, preparation method and pharmaceutical compositions containing same |
| 07/13/2005 | CN1210066C Cloning pigs using donor nuclei from differentiated cells |
| 07/13/2005 | CN1210044C Chinese medicine for gastrointestinal cances and its preparation |
| 07/13/2005 | CN1210029C Pharmaceutical use for piperine and method for cosmetically promoting the natural coloration of the skin |
| 07/13/2005 | CN1210023C Carboplatin precursor liposome injection and preparing process thereof |
| 07/13/2005 | CN1210020C Use of biodegradable microspheres for delivery of anticancer for treatment of glioblastoma |
| 07/12/2005 | US6917616 Method and apparatus for reduction and restoration of data elements pertaining to transmitted data packets in a communications network |
| 07/12/2005 | US6916927 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction |
| 07/12/2005 | US6916923 Method for synthesizing pyrazolobenzodiazepines |
| 07/12/2005 | US6916913 Dorsalin-1 polypeptide and uses thereof |
| 07/12/2005 | US6916908 Mixture comprising blood protein of marine gastropod for treating tumors; immunotherapy; immunostimulants |
| 07/12/2005 | US6916838 1-benzylpyrazole-3-carboxylic acid tricyclic derivatives as cannabinoid receptor antagonists |
| 07/12/2005 | US6916834 Preparations and use of an Ah receptor ligand, 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 07/12/2005 | US6916833 Substituted piperidines |
| 07/12/2005 | US6916814 Methods of treating cytokine mediated diseases |
| 07/12/2005 | US6916810 αν integrin receptor antagonists |
| 07/12/2005 | US6916809 Heterocyclic acridone inhibitors of IMPDH enzyme |
| 07/12/2005 | US6916807 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 07/12/2005 | US6916804 Pyrimidine A2b selective antagonist compounds, their synthesis and use |
| 07/12/2005 | US6916798 Inhibitors of glycogen synthase kinase-3 (GSK-3), a serine/threonine protein kinase; for treatment and prevention of diabetes and Alzheimer's disease |
| 07/12/2005 | US6916793 Treating tumor cells with a selenium prodrug lyase and a selenium-containing prodrug such as selenocysteine, selenohomocysteine, selenomethionine or selenoethionine. |
| 07/12/2005 | US6916788 Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
| 07/12/2005 | US6916625 Artery- and vein-specific proteins and uses therefor |
| 07/12/2005 | US6916485 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar |
| 07/12/2005 | US6916476 Keyhole limpet hemocyanin (klh); anticancer agents; treating melanoma |
| 07/12/2005 | US6916461 Metal complexes that contain perfluoroalkyl, process for their production and their use in NMR diagnosis |
| 07/12/2005 | CA2341739C Quinolin-2-one derivatives useful as anticancer agents |
| 07/12/2005 | CA2323008C Pharmaceutically active compounds |
| 07/12/2005 | CA2298142C Soya extract, process for its preparation and pharmaceutical composition |
| 07/12/2005 | CA2105867C Novel imidazole derivatives, their preparation and therapeutic applications |
| 07/07/2005 | WO2005061725A1 Methods for detecting markers associated with endometrial disease or phase |
| 07/07/2005 | WO2005061701A1 Process for producing polymer composite of protein |
| 07/07/2005 | WO2005061697A1 Process for producing engineered targeted t cell and medicine |
| 07/07/2005 | WO2005061541A1 Anti-igf-i receptor antibody |
| 07/07/2005 | WO2005061523A1 Glycosaminoglycan (gag) mimetics |
| 07/07/2005 | WO2005060992A1 Therapeutic agents and uses therefor |
| 07/07/2005 | WO2005060973A1 Reduction of toxicity of multi-targeting antifolates |
| 07/07/2005 | WO2005040045A3 Method for the production of trans- or cis-diammoniumdichlorodihydroxoplatinum (iv) and use thereof for the production of pharmaceutical agent |
| 07/07/2005 | WO2005037839A8 Norcantharidin derivative compounds, method for the production thereof, compositions containing said compounds and the use thereof |
| 07/07/2005 | WO2005007603A3 Fluorocombretastatin and derivatives thereof |
| 07/07/2005 | WO2004080425A3 Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| 07/07/2005 | WO2004035629A9 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 07/07/2005 | WO2004022560A9 Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 07/07/2005 | WO2003089583A3 Tissue specific genes and gene clusters |
| 07/07/2005 | WO2003083069A8 Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb |
| 07/07/2005 | WO2003061571A3 Combination il-2/anti-herz antibody therapy for cancers characterized by overexpression of the her2 receptor protein |
| 07/07/2005 | WO2003053360A3 Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
| 07/07/2005 | US20050148772 Methods and compositions for detecting polynucleotide duplex damage and errors |
| 07/07/2005 | US20050148664 therapy of NF-kappaB mediated diseases; mitochondrial diseases; transplantation medicine |
| 07/07/2005 | US20050148662 compounds possess the ability to recognize and promote oxidation and allow for scission of a nucleic acid at specific positions and splitting (if exposed to piperidine) |
| 07/07/2005 | US20050148661 calcium is in gluconate, chloride, bromogalactogluconate, gluconolactate or carbonate form, and the magnesium is in sulfate or pidolate form |
| 07/07/2005 | US20050148651 Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl-(amine- derived)] compounds and analogues thereof, and to products obtained therefrom |
| 07/07/2005 | US20050148644 Ligands for Inosine-5'-monophosphate dehydrogenase; antiviral, antiinflammatory, antibiotics, transplant rejection, autoimmune disease, , antipsoriatic immunosuppressants; 3-uriedo benzyl carbamate derivatives; high potency, side effects reduction; bioavailability; antivascular hyperproliferative |
| 07/07/2005 | US20050148636 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/07/2005 | US20050148625 Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions |
| 07/07/2005 | US20050148624 Enzyme inhibitors with isoquinolinone structures |
| 07/07/2005 | US20050148619 Sulfonamido ether substituted imidazoquinolines |
| 07/07/2005 | US20050148613 Carbonylamino-derivatives as novel inhibitors of histone deacetylase |
| 07/07/2005 | US20050148609 Tetrazole substituted quinazoline compounds for antiproliferation agents |
| 07/07/2005 | US20050148607 Administering to show overactivation or expression from diagnosis of diseases, immunoassay, anticancer agents or skin disorders |
| 07/07/2005 | US20050148599 Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| 07/07/2005 | US20050148593 Compounds, compositions, and methods |
| 07/07/2005 | US20050148591 Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof |
| 07/07/2005 | US20050148577 2-methyl-1,8-dioxa-dibenzo[e,h]azulene; potentiation; dual inhibitors of tumour necrosis factor(alpha) and interleukin 1; antiinflammatory, analgesics |
| 07/07/2005 | US20050148575 (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury |
| 07/07/2005 | US20050148537 Immunostimulatory nucleic acid molecules |
| 07/07/2005 | US20050148526 Methods of obtaining isoform specific expression in mammalian cells |
| 07/07/2005 | US20050148524 Treating multiple myeloma via administering thalidomide and topoisomerase inhibitor such as irinotecan; side effect reduction |
| 07/07/2005 | US20050148521 Coadministration with non-steroidal antiinflammatory agent allows for lower dosage of cyclophosphamide; side effect reduction; kits |
| 07/07/2005 | US20050148515 Peptidomimetics; determining ability to bind growth hormone secretagogue; ghrelin agonists; appetite stimulation; dietetics |
| 07/07/2005 | US20050148504 Cysteine protease inhibitor |
| 07/07/2005 | US20050148502 Compositions and methods for preventing and treating cancer via modulating ube1l, isg15 and/or ubp43 |
| 07/07/2005 | US20050148498 Metalloprotease inhibiting activity, in particular collagenase and gelatinase, treating humans or mammals suffering from a condition or disease related to excessive degeneration of support by a metalloprotease; treat inflammatory diseases: arthrosis, parodontosis or ulcers |
| 07/07/2005 | US20050148075 With binding specificity for target nucleotides containing one or GNN triplets; regulating gene expression |
| 07/07/2005 | US20050148072 Human liver progenitors |
| 07/07/2005 | US20050148062 Transgenic microorganisms comprising apoptosis associated genes for use as tools in identifying modulators for prevention and treatment of cell proliferative disorders |
| 07/07/2005 | US20050148034 Using reduced microvessel outgrowth of pluripotent stem cells as diagnostic indicator angoigenseis inhibition; antitumor agents |
| 07/07/2005 | US20050148014 Regulation of human P2Y1-like G protein-coupled receptor |